Compass Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 22 →Insiders2 insiders bought $75,600 in 2 open-market buys. No sales.→HoldersTang 10.0%Orbimed 8.5%Montanova Capital 7.8%→Financing →PeersClosest companies: RVMD, NXTC, KAPA→
From the filings
Figures
- Revenue
- $0.00last 12 months
- Net income
- −$73.4Mlast 12 months
- Operating cash flow
- −$53.2Mlast 12 months
- Cash and equivalents
- $35.5Mat the last balance sheet
- Shares outstanding
- 180.1M shareson issue